Related Experiment Video
Updated: Jun 12, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Impact of phosphate binder type on coronary artery calcification in hemodialysis patients
R Shantouf1, N Ahmadi, F Flores
1Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA.
Insights
Calcium-free sevelamer use in maintenance hemodialysis patients was associated with lower coronary artery calcification (CAC) compared to calcium-based phosphate binders (CBPB). This finding suggests sevelamer may be a safer option for managing phosphate levels and cardiovascular risk in CKD patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Coronary artery calcification (CAC) is highly prevalent in chronic kidney disease (CKD) patients, particularly those on maintenance hemodialysis (MHD).
- Phosphate binders are crucial for managing hyperphosphatemia in CKD, but their impact on cardiovascular calcification varies.
- Calcium-based phosphate binders (CBPB) have been linked to increased calcification, prompting research into alternatives like calcium-free binders.
Purpose of the Study:
- To investigate the association between sevelamer (a calcium-free phosphate binder) and coronary artery calcification (CAC) in MHD patients.
- To compare CAC scores in MHD patients treated with sevelamer versus those treated with CBPB.
- To determine if sevelamer monotherapy is associated with reduced CAC compared to CBPB monotherapy in MHD patients.
Main Methods:
- A cross-sectional study involving 117 maintenance hemodialysis (MHD) patients.
- Patients were categorized into two groups: those taking only CBPB (n=60) and those taking only sevelamer (n=57).
- Coronary artery calcium scores (CACS) were assessed using computerized tomography; logistic regression analyzed the odds of significant CAC.
Main Results:
- Despite a higher prevalence of diabetes mellitus (DM) in the sevelamer group (58% vs. 35%), CACS was significantly lower in sevelamer users (283 ± 83) compared to CBPB users (494 ± 94; p=0.02).
- After adjusting for covariates, CBPB use was associated with significantly higher odds of severe CAC (CACS ≥ 400) compared to sevelamer use (OR=4.35; 95% CI: 1.5-9.9; p=0.008).
Conclusions:
- Significant coronary artery calcification (CAC) is more prevalent in maintenance hemodialysis (MHD) patients treated with calcium-based phosphate binders (CBPB) compared to those on sevelamer monotherapy.
- These findings suggest that calcium-free phosphate binders like sevelamer may play a role in mitigating cardiovascular calcification in MHD patients.
- Further prospective studies are warranted to confirm the cardiovascular benefits of sevelamer in this high-risk population.
Aims:
In individuals with chronic kidney disease (CKD), including those undergoing maintenance hemodialysis (MHD), coronary artery calcification (CAC) is common. We hypothesized that, in MHD patients, intake of the calcium-free phosphate binder sevelamer is associated with lower CAC compared to calcium-based phosphate binders (CBPB).
Material And Methods:
This is a cross-sectional study of MHD patients, who underwent computerized tomography to assess coronary artery calcium scores (CACS). Patients were stratified into two mutually exclusive groups based on taking only a CBPB vs. sevelamer. Logistic regression was used to calculate adjusted odds ratio (OR) of CACS > or = 400, CACS 100 < or =; CACS < 400, 10 < or =; CACS < 100 vs. CACS < 10.
Results:
117 MHD patients were either on a CBPB alone (n = 60) or sevelamer alone (n = 57). Despite increased prevalence of DM in the sevelamer group (58%) as compared to the CBPB group (35%), CACS was significantly lower with sevelamer use (283 + or - 83 vs. 494 + or - 94, p = 0.02). The OR of significant CACS > or =; 400 vs. CAC < 10 was 4.35 (95% confidence interval: 1.5 - 9.9, p = 0.008) for CBPB compared with sevelamer, after controlling for case-mix, cholesterol-lowering medication, DM, and inflammatory markers.
Conclusion:
In our cohort, significant CAC was significantly more prevalent among MHD patients taking CBPB as compared to sevelamer monotherapy.
More Related Videos
08:43Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
06:57Semi-Automatic Graphical Tool for Measuring Coronary Artery Spatially Weighted Calcium Score from Gated Cardiac Computed Tomography Images
Published on: September 22, 2023
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Peritoneal Dialysis III: Nursing Management
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Chronic Kidney Disease II: Clinical Manifestations